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Abstract
Background: Cystic fibrosis (CF) airway pathology is a fatal, autosomal, recessive genetic disease characterized by
extensive lung inflammation. After induction by TNF-a, elevated concentrations of several pro-inflammatory
cytokines (i.e. IL-6, IL-1b) and chemokines (i.e. IL-8) are released from airway epithelial cells. In order to reduce the
excessive inflammatory response in the airways of CF patients, new therapies have been developed and in this
respect, medicinal plant extracts have been studied. In this article we have investigated the possible use of
bergamot extracts (Citrus bergamia Risso) and their identified components to alter the expression of IL-8 associated
with the cystic fibrosis airway pathology.
Methods: The extracts were chemically characterized by
1H-NMR (nuclear magnetic resonance), GC-FID (gas
chromatography-flame ionization detector), GC-MS (gas chromatography-mass spectrometry) and HPLC (high
pressure liquid chromatography). Both bergamot extracts and main detected chemical constituents were
assayed for their biological activity measuring (a) cytokines and chemokines in culture supernatants released
from cystic fibrosis IB3-1 cells treated with TNF-a by Bio-Plex cytokine assay; (b) accumulation of IL-8 mRNA
by real-time PCR.
Results: The extracts obtained from bergamot (Citrus bergamia Risso) epicarps contain components displaying an
inhibitory activity on IL-8. Particularly, the most active molecules were bergapten and citropten. These effects have
been confirmed by analyzing mRNA levels and protein release in the CF cellular models IB3-1 and CuFi-1 induced
with TNF-a or exposed to heat-inactivated Pseudomonas aeruginosa.
Conclusions: These obtained results clearly indicate that bergapten and citropten are strong inhibitors of IL-8
expression and could be proposed for further studies to verify possible anti-inflammatory properties to reduce lung
inflammation in CF patients.
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Cystic fibrosis (CF) pulmonary disease is an autosomal
recessive disease caused by defective function of the
CFTR protein product, a cAMP-regulated chloride
channel [1]. In addition to its primary biological role,
CFTR is likely to affect the expression of a number of
gene products, including proteins of the signalling path-
ways of the inflammatory response [2,3]. One of the
major problems of CF is a chronic inflammatory process
[4], leading to elevated concentrations of several pro-
inflammatory cytokines (i.e. IL-6, TNF-a,I L - 1 b)a n d
chemokines (i.e. IL-8), released from airway epithelial
cells and found in the bronchoalveolar fluid of CF
patients [5-8]. The lung inflammation is characterized
by a sustained accumulation of neutrophils, high proteo-
lytic activity and elevated levels of cytokines and chemo-
kines, such as interleukin (IL)-8 [9,10]. Massive
infiltration of neutrophils in airways, enhanced adher-
ence of neutrophils to CF airway epithelial cells [11,12],
elevated levels of cytokines and chemokines in bronch-
oalveolar lavage fluids such as IL-1b and IL-8 [13,14],
may contribute to an over exuberant pro-inflammatory
response in lungs of patients with CF.
IL-8 is clearly involved in inflammatory processes
associated with CF [15,16]. Interestingly, IL-8 exhibits
high release also in CF cells infected with Pseudomonas
aeruginosa or induced with TNF-a [17].
So far, therapies for cystic fibrosis have been directed
at improving airway clearance of secretions and treating
endobronchial infection. Recently, there is a growing
interest in developing therapies aimed at reducing the
excessive inflammatory response in the airways [18,19].
In this respect, extracts from plants used in ethnic med-
icine are of great interest, as many of them are known
to present anti-inflammatory properties [20-29]. For
example, Darshan and Doreswamy [26] described the
anti-inflammatory activity of drugs derived from 38
medicinal plants. In this review a clear role of botanical
plants (including polysaccharides, terpenes, curcumi-
noids and alkaloids) was reported as alleviating inflam-
matory diseases, such as arthritis, rheumatic pathologies,
acne skin allergy and ulcers.
Bergamot (Citrus bergamia Risso) is a typical fruit
of the Reggio Calabria province in Southern Italy,
where it is mainly used for its essential oil extracted
from the peel. Bergamot essential oil is widely used in
the pharmaceutical industry because of the antibacter-
ial and antiseptic activity [30] of its volatile fraction,
where the major component is the limonene [31].
However, bergamot peel contains also non-volatile
components, such as coumarins and furanocoumarins
[32]. This is not surprising, since furocoumarins and
coumarins are generally distributed throughout the
Citrus species [33], being the highest amounts are
found in Citrus peel oils [34]. These compounds
are reported to have a broad spectrum of biological
activities, including antimicrobial [35], anti-platelet-
aggregation [36], anti-mutagenic [37] and anti-inflam-
matory [38,39] activities.
In the present study, we analyzed the effects of berga-
mot extracts and their putative isolated compounds on
the production of IL-8 in cystic fibrosis IB3-1 and CuFi-
1 cells [27,40-42] induced to hyper secretion of pro-
inflammatory chemokines following treatment with
TNF-a [17,43,44] or exposure to heat-inactivated Pseu-
domonas aeruginosa.
Materials and methods
Plant material and extraction procedures
Commercial mature Citrus bergamia fruits belonging to
three different stocks from organic farming in Southern
Italy were purchased and manually processed to comple-
tely remove the epicarp. The raw plant material
obtained (150 g for each sample stock) were immedi-
ately suspended in 600 mL chloroform and processed
for the extractions. The suspension was homogenized
f o r5m i na n ds u b m i t t e dt os o n i c a t i o ni na nu l t r a s o u n d
b a t h( U l t r a s o n i kM o d .1 0 4 × ,N e yD e n t a lI n c . ,U S A )i n
the dark at a constant temperature of 25°C. Subse-
quently, the samples were filtered and centrifuged for 20
min at 3000 rpm. The residue was re-extracted with 400
mL chloroform following the same procedure previously
described. The collected chloroform extracts, named
“extract 1”, were partially reduced in volume with Rota-
vapor and then completely dried under nitrogen flow.
The total extraction yield was 3.6 ± 0.2%. Aliquots (5 g)
of these sample extracts (extract 1) were subjected to
fractional distillation at 350-400 Pa and 40°C, as
described elsewhere [45], in order to completely remove
volatile terpene compounds, and partly oxygenated che-
micals. The sediment obtained at the end of distillation
corresponded to the extract 2 samples with an extrac-
tion yield of 40.3 ± 0.8%. One g of samples of extract 2
w a st h e nr e - s u s p e n d e di n2 0m Ld i e t h y le t h e r ,v i g o r -
ously shaken for 30 min and centrifuged. The superna-
tant was removed and the residue, corresponding to
extract 3 samples, was collected, dried under nitrogen
flow and weighed (yield: 65.1 ± 1.5%). For all laboratory
processing care was taken to protect the operations
from light and oxidizing conditions. All the solvents
used were purchased from Sigma-Aldrich, Reagent Eur-
opean Pharmacopoeia purity. All the samples (extract 1,
extract 2, extract 3) were stored in the dark in glass
vials with Teflon-sealed caps at 2.0 ± 0.5°C until ana-
lyses by GC-FID, GC-MS, and HPLC to identify and
quantify putative bioactive compounds.
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The sample extracts were analyzed and the relative peak
areas for volatile and oxygenated components weighted
by GC-FID. The relative percentages were determined
using GC TRACE Thermoquest, equipped with auto-
sampler Triplus (Thermo Electron Corporation). The
column was VF-5ms, 30 m × 0.25 mm. Flow rate was
1.0 mL/min He, and split 1:50. Injector temperature,
300°C; detector temperature, 350°C. Oven temperature
was initially 55°C, raised to 100°C at a rate of 1°C/min,
and then raised to 250°C at a rate of 5°C/min and finally
held at that temperature for 15 min. One μl of each
sample (15 mg/mL CH2Cl2) was injected. The percen-
tage composition of volatile and oxygenated components
was computed by the normalization method from the
GC peak areas (data integration software: Jasco-Borwin
version 1.5, JMBS Developments, Fontaine, France),
without correction factors. Identification was performed
by a Varian GC-3800 gas chromatograph equipped with
a Varian MS-4000 mass spectrometer with electron
impact and hooked to a NIST (National Institute of
Standards and Technology) library. A Varian FactorFour
VF-5ms poly-5% phenyl-95%-dimethyl-siloxane bonded
phase column (i.d., 0.25 mm; length, 30 m; film thick-
ness, 0.15 μm) was used. Operating conditions were as
follows: injector temperature 300°C; FID temperature
300°C, Carrier (Helium) flow rate 1.0 mL/min and split
ratio 1:50. The MS (mass spectrometry) conditions were
as follows: ionization voltage, 70 eV; emission current,
10 μAmp; scan rate, 1 scan/s; mass range, 29-400 Da;
trap temperature, 150°C, transfer line temperature, 300°
C. The main compounds were identified by comparing
their relative retention time, KI (Kovats Index) and the
MS fragmentation pattern with those of essential oils of
known composition, with pure compounds and by
matching the MS fragmentation patterns with the above
mentioned mass spectra libraries and with those in the
literature [18]. To determine the Kovats index of the
components, a commercial 24 aliphatic hydrocarbons
mixture (Sigma-Aldrich) was added to the sample
extracts before injecting in the GC-MS equipment and
analyzed under the same conditions as above.
HPLC analysis
HPLC analysis was performed to quantify the main con-
stituents of the non-volatile fraction of bergamot essen-
tial oil. Therefore, pure commercial standards of
bergaptol, bergamottin, bergapten, citropten and 5-gera-
nyloxy-7-methoxycoumarin (Extrasynthese, France) were
used as external standards to set up and calculate
appropriate calibration curves. The experimental condi-
tions were performed using a Jasco modular HPLC
(Tokyo, Japan, Model PU 2089) coupled to a Diode
Array apparatus (MD 2010 Plus) linked to an injection
valve with a 20 μL sampler loop. The column used was
a Tracer extrasil ODS2 25 × 0.46 cm, with a flow rate
of 1.0 mL/min. The mobile phase employed consisted of
the solvent solution B (methanol) and A (water/formic
acid = 95/5). The gradient system adopted was charac-
terized by 4 steps: 1. isocratic, with solvent solution B/A
= 40/60 (%), for 2 min; 2. the solvent solution B raised
progressively from 40 to 60% in 18 min (from min 2 to
min 20) until reaching the ratio B/A = 60/40 (%); 3. the
solvent solution B then raised 100% in 4 min (from min
20 to min 24); 4. the solvent solution ratio reached B/A
= 40/60 in 4 min (from min 24 to min 28). Injection
volume was 40.0 μl. Chromatograms were recorded and
peaks from bergamot sample extracts were identified by
comparing their spectra with spectra obtained with pure
standards. Peak area was determined by integration
using dedicated Borwin software (Borwin ver. 1.22,
JMBS Developments, Grenoble, France). The qualitative
and quantitative analyses of each extract were per-
formed three times.
Cell cultures
IB3-1 cells and CuFi-1 cell lines were obtained from
human bronchial epithelium derived from a CF patient
with ΔF508del/W1282X mutant genotype (IB3-1 cells)
[27] and from a CF patient with a F508del/F508del
mutant genotype (CuFi-1 cells) [42]. These cells were
g r o w ni nL H C - 8b a s a lm e d i u m( Biofluids), supplemen-
ted with 5% FBS in the absence of gentamycin. All cul-
ture flasks and plates were coated with a solution
containing 35 mg/ml bovine collagen (Becton-Dickin-
son), 1 mg/ml bovine serum albumin (Sigma) and 1 mg/
ml human fibronectin (Becton-Dickinson). Treatment
with TNF-a (80 ng/ml) was performed on 70% conflu-
ent cells for 24 hours. Cell number/ml was determined
after trypsin treatment by using a model ZBI Coulter
Counter (Coulter Electronics, Hialeah, FL, USA). Cells
were seeded at the initial concentration of 30,000 cells/
cm
2 and the cell number/ml determined as IC50 after 3
days of culture, when untreated cells are in log phase of
cell growth.
Quantification of IL-8 transcripts
Total RNA was isolated (High Pure RNA isolation kit,
Roche), retro transcribed (Promega Corporation, Madi-
son, Wisconsin, USA) and the resulting cDNA was
quantified by relative quantitative real-time PCR [46].
The sequences of the oligonucleotides used for amplifi-
cation of IL-8 mRNA were: 5’-GTG CAG TTT TGC
CAA GGA GT-3’ (forward) and 5’-TTA TGA ATT
CTC AGC CCT CTT CAA AAA CTT CTC-3’ (reverse);
for b-actin mRNA: 5’-TGA CGG GGT CAC CCA CAC
TGT GCC CAT CTA-3’ (forward); 5’-CTA GAA GCA
TTT GCG GTG GAC GAT GGA GGG-3’ (reverse).
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i n g5 0m MK C l ,1 0m MT R I S - H C lp H8 . 8 ,1 . 5m M
MgCl2 by using 1U/reaction of Taq DNA polymerase,
100 μMd N T P s ,0 . 5μM PCR primers. The 30 PCR
cycles used were as follows: denaturation, 30 s, 94°C;
annealing, 60 s, 68°C; elongation, 60 s, 72°C. The length
of the IL-8 PCR product was 236 bp [17,40]. The mar-
ker pUC mix 8 (Fermentas, Milan, Italy) at 0.5 μg/lane
was used. For quantitative real-time PCR reaction, 0,5/
20 μl aliquots of cDNA were used for each Sybr Green
real-time PCR reaction to quantify the relative tissue
expression of IL-8 transcripts. Each 25 μlo ft o t a lr e a c -
tion volume contained 0.5 μl of cDNA, 10 pmol of pri-
mers, 1 × iQ™ SYBR
® Green Supermix (Bio-Rad
Laboratories, Hercules, CA). Real-time PCR reactions
were performed for a total of 40 cycles (95°C for 10 s,
68°C for 30 s, and 72°C for 40 s) using an iCycler IQ
®
(Bio-Rad Laboratories, Hercules, CA). The relative pro-
portions of each template amplified were determined
based on the threshold cycle (Tc) value for each PCR
reaction. The ΔΔCt method was used to compare gene
expression data. RT-PCR was usually performed in
duplicate using two cDNA preparations for each inde-
pendent experiment. Mean ± S.D. values were deter-
mined for each fold difference for at least three
independent experiments. Amplification of human b-
actin cDNA served as internal standards (housekeeping
gene). Duplicate negative controls (no template cDNA)
were also run with every experimental plate to assess
specificity and i
IL-8 release
IL-8 in tissue culture supernatants released from the
cells under analysis was measured by Bio-Plex cytokine
assay (Bio-Rad Laboratories, Hercules, CA) [47,48] as
described by the manufacturer. The Bio-Plex cytokine
assay is designed for the multiplexed quantitative mea-
surement of multiple cytokines in a single well using as
little as 50 μl of sample. In our experiments, the pre-
mixed singleplex beads of the Bio-Plex human cytokines
IL-8 were used. 50 μl of IL-8 standards or samples
(supernatants recovered from treated cells and diluted
to 2 μg/μl) were incubated with 50 μl of anti-IL-8 conju-
gated beads in 96-well filter plates for 30 min at room
temperature with shaking. Plates were then washed by
vacuum filtration three times with 100 μl of Bio-Plex
wash buffer, 25 μl of diluted detection antibody were
added, and plates were incubated for 30 min at room
temperature with shaking. After three filter washes, 50
μl of streptavidin-phycoerythrin was added, and the
plates were incubated for 10 min at room temperature
with shaking. Finally, plates were washed by vacuum fil-
tration three times, beads were suspended in Bio-Plex
assay buffer, and samples were analyzed on a Bio-Rad
96-well plate reader using the Bio-Plex Suspension
Array System and Bio-Plex Manager software (Bio-Rad
Laboratories, Hercules, CA).
Statistical analysis
The statistical significance of difference in between dif-
ferent treatments, was analyzed using one-way analysis
of variance (ANOVA) and the Student-Newman Keuls
test. p values lower than 0.05 were considered signifi-
cant (*).
Results
Effects of bergamot extracts on the expression of IL-8
mRNA in IB3-1 cells following TNF-a treatment: RT-PCR
analysis
In order to determine the effects of bergamot extracts
on mRNA accumulation, the expression of IL-8 gene
was studied by RT-PCR analysis of RNA extracted from
TNF-a treated IB3-1 cells cultured in the presence of
increasing concentrations of bergamot extracts for 24
hours. These concentrations were chosen according to
the IC50 values reported in Table 1 and concerning a
study of the antiproliferative effects on IB3-1 cells. As
target gene, we analysed the accumulation of IL-8
mRNA because IL-8 gene (a) encodes one of the most
e x p r e s s e di n t e r l e u k i n si nI B 3 - 1c e l l s[ 1 7 ] ,( b )i ti s
strongly induced following TNF-a treatment [17], and
(c) it is clearly involved in inflammatory processes asso-
ciated with CF [15,16]. Interestingly, IL-8 exhibits the
highest release also in CF cells infected with Pseudomo-
nas aeruginosa [40].
Panel A of Figure 1 shows representative results
obtained by amplifying RNA from untreated IB3-1 cells
(triangles), TNF-a treated IB3-1 cells (squares) or IB3-1
cells treated with TNF-a i nt h ep r e s e n c eo fI C 50 con-
centration of extract 3 (crosses) using primer specific
for IL-8 and b-actin RNA sequences. The b-actin gene
w a su s e da sr e f e r e n c eg e n ei no r d e rt on o r m a l i z e dt h e
IL-8 mRNA expression. Clear induction of IL-8 tran-
scripts following TNF-a treatment is evident. Significant
inhibitory effects were detected following exposure of
TNF-a treated IB3-1 cells to IC50 concentration of
extract 3.
Table 1 IC50 values for bergamot Extracts and relative
identified compounds on IB3-1 cell lines
IC50
Extract 1 14.5 μg/ml ± 1.5
Extract 2 20.7 μg/ml ± 1.3
Extract 3 30.1 μg/ml ± 3.6
Bergapten 155.8 μM ± 43.6
Bergamottin 43.15 μM ± 6.2
Citropten 235 μM ± 38.2
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results obtained by analysing the real-time quantitative
RT-PCR data concerning the effects of bergamot
extracts on IL-8 mRNA accumulation with respect to b-
actin transcripts. The first set of results consistently
demostrate a strong increase of IL-8 mRNA transcript
in TNF-a treated IB3-1 cells (average, 34 fold, p < 0.01).
In addition, the results obtained indicate that IL-8
mRNA expression is much lower in TNF-a treated IB3-
1 cells cultured in the presence of bergamot extracts.
More in detail, extract 1 and extract 3, even when used
at IC25 concentrations, display high level of inhibition of
TNF-a induced IL-8 mRNA accumulation. IC50 concen-
trations are necessary to obtain similar inhibitory effects
using extract 2.
Effects of bergamot extracts on the expression of IL-8
genes induced in IB3-1 cells following TNF-a treatment: a
Bio-plex analysis
In consideration of the inhibitory activity on IL-8
mRNA accumulation, Bio-plex experiments were per-
formed to verify the possible effects of bergamot
extracts on IL-8 release. IB3-1 cells were treated with 80
ng/ml TNF-a in the presence of increasing amounts
(IC25-IC50-IC75)o fb e r g a m o te x t r a c t s .A f t e r2 4h o u r s ,
recovered supernatants were analyzed using the Bio-Plex
human cytokine IL-8 single-plex (Bio-Rad). When IB3-1
cells were induced with TNF-a and cultured in the pre-
sence of bergamot extracts, some important differences
in IL-8 release occurred, as reported in Figure 2, i.e. the
TNF-a induced release of IL-8 (pg/ml) was strongly
reduced using extract 1 and 3 at IC50 concentrations.
The effect was found to be concentration-dependent.
The results obtained indicate a strong inhibition of IL-8
release using extracts 3, even when it was used at IC25
concentration, while extract 2 showed inhibitory activity
only at IC75 concentration. Low level of inhibition was
on the contrary detected analyzing the release of VEGF
(data not shown). These data suggest that bergamot
extracts might specifically inhibit the expression of the
IL-8 pro-inflammatory gene.
These data are in agreement with the results obtained
using the RT-PCR approach (see Figure 1), and sustain
the concept that bergamot extracts are potent inhibitors
of the TNF-a induced expression of the IL-8 gene in
IB3-1 cells.
Phytochemical investigation
In consideration of the biological activity shown in
Figures 1 and 2, the phytochemical investigation of the
Figure 1 E f f e c t so fb e r g a m o te x t r a c t so nI L - 8m R N A
accumulation. IB3-1 were treated with ng/ml TNF-a in the
presence of increasing concentrations of bergamot extracts for 24
hours, RNA was extracted and RT-PCR performed with primers
specific for IL-8 and b-actin RNA sequences. A. Representative
quantitative RT-PCR analysis. Triangles: RNA from untreated IB3-1
cells; squares: TNF-a treated IB3-1 cells; crosses: IB3-1 cells treated
with IC50 extract 3. B: Effects of bergamot extracts on IL-8 mRNA
accumulation with respect to b-actin transcripts; (a): extracts added
at IC25; (b): extracts added at IC50. Results represent the average ± S.
D. of three independent experiments. For each experiment triplicate
RT-PCR determinations were performed. (*) p < 0.05.
Figure 2 Effects of bergamot extracts on the IL-8 release.I B 3 - 1
cells were treated with 80 ng/ml of TNF-a and increasing amounts
(a: IC25; b:IC50; c:IC75) of bergamot extracts. After 24 hours, recovered
supernatants were analyzed using the Bio-Plex human cytokine IL-8
single-plex (Bio-Rad). (-): untreated IB3-1 cells; (+): IB3-1 cells treated
with TNF-a. Results represent the average ± S.D. of three
independent experiments. For each experiment duplicate
determinations were performed. (*) p < 0.05.
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obtain a qualitative and quantitative determination of
the chemical constituents of the extracts, with particular
reference to non-volatile fraction chemicals, i.e. coumar-
ins and psoralens. The link between these phytochem-
ical aims and the bioactivity assays targets was to
determine the role, if any, of the non-volatile fraction,
or of their constituents individually, with or without the
synergic interaction of volatile chemicals, in the modula-
tion of IL-8 gene expression in in vitro cell models.
The chloroform extract (extract 1 samples) composi-
tion was similar to that in bergamot essential oil with
two significant fractions: a) monoterpenes and their cor-
related compounds and b) coumarins and psoralens
[32]. The extraction procedures followed led to products
(extract 2 and extract 3 samples) with a progressive
decrease of volatile compounds and an increase of the
non-volatile fraction (coumarins and psoralens) as deter-
mined by semi-quantitative combined GC-FID and GC-
MS analyses (Figure 3). Extract 1 samples showed the
presence of linalyl acetate (36.12%), linalool (27.35%)
and limonene (18.78%) as the main constituents, as for
bergamot essential oil, while coumarins and psoralens
were 4.64% (Figure 3). Extract 2 samples showed an
important reduction of linalyl acetate (27.45%) and a
dramatic decrease of other terpene compounds. Many
minority chemicals were not detectable while others,
such as limonene, showed a reduction of 93.2%. extract
3 samples gave an even more noticeable reduction of
terpene compounds, with linalyl acetate (0.43%), g-terpi-
nene (0.17%) and b-myrcene (0.53%) as the only volatile
fraction chemicals, against an increase of coumarins and
psoralens of 45.5% and 95.2% in the extract 2 and
extract 3 samples respectively (Figure 3).
HPLC analyses were performed to detect and quantify
coumarins and psoralens reputed to be representative of
the non volatile fraction and of the bioactivity of berga-
mot crude drug and derived products [32]. Citropten
(5,7-dimethoxycoumarin), bergamottin (5-geranyloxyp-
soralen) and bergapten (5-methoxypsoralen) were identi-
fied in all bergamot extract samples. In samples of
extract 1 bergamottin and bergapten represented 2.57%
and 2.89% respectively, while citropten was detected in
lower concentrations (0.37%). In samples of extract 2
concentrations of bergamottin, bergapten and citropten
were 9.44%, 27.26%, 1.14%, while in samples of extract 3
concentrations were 3.10%, 85.75% and 0.51% respec-
tively (Figure 4).
In consideration of the fact that extract 3 was the
most active on inhibition of TNF-a induced IL-8
mRNA accumulation and IL-8 secretion by treated IB3-
1 cells, we hypothesized that the coumarin/psoralen
fractions of the extracts werea m o n gt h o s er e s p o n s i b l e
for the biological activity. Therefore, the activity of
citropten, bergapten and bergamottin have been further
analyzed.
Effects of identified compounds in bergamot extracts on
expression of IL-8 genes in TNF-a treated IB3-1 cells
In order to determine effects of the three major com-
pounds identified on IL-8 mRNA accumulation, we ana-
lyzed, by semi-quantitative RT-PCR, the levels of IL-8
mRNA in TNF-a treated IB3-1 cells [49] cultured for
24 hours in the presence of increasing concentrations of
bergamottin, bergapten, citropten (Figure 5). These con-
centrations were chosen according to IC50 values
obtained in experiments on anti-proliferative activity
determined on IB3-1 cells and reported in Table 1.
The preliminary results obtained indicate that accu-
mulation of IL-8 mRNA is lower in TNF-a treated
IB3-1 cells cultured in thep r e s e n c eo fb e r g a p t e no r
citropten, administered at IC50 concentrations, while
bergamottin does not show inhibitory effects at the
same concentrations (Figure 5A). The accumulation of
b-actin mRNA (used as housekeeping gene) does not
Figure 3 Phytochemical composition of the bergamot extracts.
The chemical characterizations of bergamot extracts 1 (A), 2 (B) and
3 (C) were performed by GC-MS and GC-FID and expressed as
percentage weight/weight [w/w(%)]. The analyses were performed
three times.
Borgatti et al. BMC Biochemistry 2011, 12:15
http://www.biomedcentral.com/1471-2091/12/15
Page 6 of 12change following treatment with bergamot analogues
(Figure 5B).
On the basis of this first set of results, showing that ber-
gapten and citropten exhibit an interesting inhibitory activ-
ity on mRNA accumulation, real-time quantitative RT-PCR
analysis was performed to better quantify inhibitory effects
of these two compounds on RNA production in IB3-1 cells
induced with TNF-a and treated with IC25 and IC50 con-
centrations of citropten or bergapten; in these experiments
IL-8 mRNA accumulation was compared with that of the
internal control b-actin mRNA. Panel A of Figure 6 shows
the representative results obtained by amplifying RNA
from untreated IB3-1 cells (triangles), or cells treated with
TNF-a (squares), in the presence of citropten (diamonds,
IC50 concentration) and bergapten (crosses, IC50 concen-
tration), using primers specific for IL-8 RNA. Clear induc-
tion of IL-8 transcripts following TNF-a treatment is
evident, but this increase is lower in the presence of treat-
ment with citropten or bergapten. Citropten was found to
be more efficient than bergapten in inhibiting IL-8 mRNA
accumulation. This result is more evident in Panel B of Fig-
u r e6 ,s h o w i n gas u m m a r yo ft h ed a t ao b t a i n e db yr e a l -
time quantitative RT-PCR performed to investigate the
effects on IL-8 mRNA accumulation of bergapten and
citropten at two different concentrations (IC25 and IC50).
Significant inhibitory effects on IL-8 mRNA accumulation
were detected following exposure of TNF-a induced IB3-1
cells to citropten and bergapten, even when they were
administered at IC25 concentrations. Moreover, citropten
was found to be more active than bergapten at the same
concentrations. These data are in agreement with data
obtained by semi-quantitative RT-PCR (see Figure 5), and
confirm the potent inhibitory activity of citropten and ber-
gapten on expression of the IL-8 gene in IB3-1 cells.
The results shown in Figure 6B have been also con-
firmed using Bio-plex technology to analyze the release
of IL-8 protein (pg/ml) in supernatants recovered from
IB3-1 cells induced with TNF-a and treated with citrop-
ten and bergapten at IC50 and IC25 concentrations.
These supernatants were collected before performing
the RNA extraction for real time PCR analysis. The
results, shown in Figure 6C, confirmed the inhibitory
activity of citropten and bergapten (again citropten was
f o u n dt ob em o r ea c t i v et h a nb e r g a p t e n )o ne x p r e s s i o n
of IL-8 protein in IB3-1 cell model. No inhibitory effects
on VEGF release were found (data not shown).
Effects of bergapten and citropten on IB3-1 cells based
experimental system mimicking Pseudomonas aeruginosa
infection
In order to determine the effects of bergapten and
citropten on an experimental system resembling more
closely the cystic fibrosis disease, we employed IB3-1
exposed to heat-inactivated Pseudomonas aeruginosa,
strain PAO-1. This induces an increase of cytokines and
chemokines, mimicking the infection of P.aeruginosa,
which is an important step in generating the clinical
symptoms of CF, as reported in several studies and
reviews [50,51] Figure 7A show that exposure of IB3-1
Figure 4 Characterization of the coumarin/psoralen portion of
the bergamot extracts by HPLC analysis. The percentage (w/w%
± SD) of citropten (5,7-dimethoxycoumarin), bergamottin (5-
geranyloxypsoralen) and bergapten (5-methoxypsoralen) were
determined for the three bergamot extracts by HPLC analysis.
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mRNA production, as elsewhere reported. In agreement
with the data reported in Figure 5, treatment of IB3-1
cells exposed to PAO-1 leads to sharp inhibition of IL-8
gene expression.
Effects of bergapten and citropten on CuFi-1 cystic
fibrosis cells
In Figure 7B, the experiments conducted with a second
CF cell line, CuFi-1, are reported. CuFi-1 cells were
exposed to PAO-1, in the absence or in the presence of
bergapten or citropten. Induction of IL-8 mRNA
accumulation was obtained after exposure of CuFi-1
cells to PAO-1 (Figure 7B) and IL-8 gene expression
was inhibited by bergapten and citropten.
Discussion
One of the clinical feature of cystic fibrosis (CF) is a
deep inflammatory process, which is characterized by
production and release of cytokines and chemokines,
among which interleukin 8 (IL-8) represent one of the
most important [15,16]. In fact, high levels of IL-8 are
present in CF cells infected with Pseudomonas aerugi-
nosa or induced with TNF-a [17]. Accordingly, there is
Figure 5 Effects of citropten, bergamottin and bergapten on IL-8 mRNA accumulation: semi-quantitative RT-PCR analysis. IB3-1 were
treated with TNF-a in the presence of IC25 (a) or IC50 (b) concentrations of citropten, bergapten and bergamottin as indicated for 24 hours, RNA
was extracted and RT-PCR performed with primers specific for IL-8 and b-actin RNA sequences. (-): untreated IB3-1 cells; (+): IB3-1 cells treated
with TNF-a. Results represent the average ± S.D. of three independent experiments. For each experiment triplicate RT-PCR determinations were
performed. (*) p < 0.05.
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order to reduce the excessive inflammatory response in
the airways [18,19] of CF patients. In this respect,
extracts from medicinal plants have been reported to
exhibit anti-inflammatory activities in several reports
[20-29].
The major result of this article is the finding that
extracts obtained from bergamot (Citrus bergamia
Risso) epicarps, contain components displaying an inhi-
bitory activity on IL-8 gene expression. This effect has
been confirmed both at the mRNA levels and at the
protein release level in the CF cellular model IB3-1,
induced with TNF-a and treated with low concentra-
tions of bergamot extracts.
The qualitative and quantitative determination of the
chemical constituents of the extracts, with particular
reference to non-volatile fraction chemicals, has demon-
strated the presence of citropten, bergamottin and ber-
gapten in all bergamot extract samples despite with
different amounts (%w/w) (see Figures 3 and 4). In
detail, the coumarin/psoralen portion was the major
constituent of the most active extract (extracts 3).
Accordingly, we hypothesized that the coumarin/psora-
len portion of these extracts was responsible of the bio-
logical activity.
On the other hand, the data reported in the present
paper do not clarify why extract 2 exhibited the lower
biological activity. It should be noted that the composi-
tion of extract 1 and extracts 2 is complex and, there-
fore, the presence of compounds exhibiting opposite
activity or interfering with the coumarin/psoralen com-
pounds cannot be excluded.
A second achievement of the results here presented is
the demonstration that, among the prominent cou-
marin/psoralen compounds, bergapten and citropten
were the most active molecules in reducing IL-8 mRNA
levels in TNF-a treated IB3-1 cells at IC50 concentra-
tions, while bergamottin did not show any inhibitory
effects at the same (see Figure 5) and higher doses (data
Figure 6 Effects of citropten and bergapten on TNF-a induced
IL-8 gene expression in IB3-1 cells. A,B: mRNA accumulation
studied by quantitative RT-PCR analysis; C: Bio-plex analysis of IL-8
protein present in supernatants. A. representative RT-PCR analysis.
triangles: untreated IB3-1 cells; squares: TNF-a treated IB3-1 cells;
diamonds: IB3-1 cells treated with citropten; crosses: IB3-1 cells
treated with bergapten. B: Summary of the effects of citropten and
bergapten on IL-8 mRNA accumulation with respect to b-actin
transcripts. B: Bio-plex analysis, using the Bio-Plex human cytokine
IL-8 single-plex (Bio-Rad). (-): untreated IB3-1 cells; (+):IB3-1 cells
treated with TNF-a. Results represent the average ± S.D. of three
independent experiments. For each experiment duplicate RT-PCR
determinations were performed. (*) p < 0.05.
Figure 7 Effects of citropten and bergapten on IB3-1 and CuFi-
1 cells. mRNA accumulation was studied by quantitative RT-PCR
analysis. IL-8 expression was induced by exposure of IB3-1 (A) and
CuFi-1 (B) to heat-inactivated PAO-1. White symbols: untreated IB3-1
or CuFi-1 cells, in the absence (-) or in the presence (+) of heat-
inactivated PAO-1. Grey symbols, cells treated with IC25 bergapten;
Black symbols, cells treated with IC25 citropten. Results represent the
average ± S.D. of three independent experiments. For each
experiment duplicate RT-PCR determinations were performed. (*) p
< 0.05.
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time quantitative RT-PCR and Bio-plex analyses. Citrop-
ten is more efficient than bergapten in decreasing IL-8
mRNA/protein accumulation in IB3-1 cells.
The effects of bergapten and citropten on IL-8 mRNA
accumulation were confirmed in IB3-1 exposed to heat-
inactivated PAO-1, mimicking Pseudomonas aeruginosa
infection [50]. In addition the effects of bergapten and
citropten on IL-8 mRNA accumulation have been con-
firmed using another CF cell line, CuFi-1.
Conclusion
The results obtained in this study clearly indicate that ber-
gapten and citropten are strong inhibitors of IL-8 expres-
sion and could be proposed as potential anti-inflammatory
molecules to reduce lung inflammation in CF patients.
Further experiments are required to: (a) identify other bio-
chemical targets of citropten and bergapten, as well as
whether the inhibitory effects on IL-8 gene expression are
reproducible in other cellular pathological systems in
which this chemokine plays a role; (b) determine safety,
potential toxicity, in vivo bioavailability, stability and
whether suitable concentrations can be reached following
in vivo administration and (c) in vivo anti-inflammatory
effects. We would like to point out that our in vitro study
does not guarantee for anti-inflammatory activity in vivo.
However, published results support the concept that mole-
cules affecting the expression of IL-8 in vitro on the IB3-1
system display also anti-inflammatory activity in vivo. For
instance, Bergamini et al. [52] found that exposure of IB3-
1 cells to Azitromycin (AZT) significantly decreased
gamma-glutamyltransferase (GGT) activity, restoring the
levels to those observed in non-CF cells. Interestingly, in
bronchoalveolar lavage fluid of CF mice homozygous for
the F508 del mutation, GST expression was undetectable,
suggesting novel antioxidant properties for this drug.
Another example are decoy oligonucleotides against NF-
kB, which are potent inhibitors of IL-8 gene expression in
Pseudomonas aeruginosa infected IB3-1 cells [53]. These
decoys against NF-kB were found to reduce chronic
inflammation in rats [54].
Moreover, it should be considered that coumarins com-
pounds, as reported in literature, display anti-proteinase
activity [55]. For example, serin proteinase is capable to
degradate the matrix proteins and is involved in several
inflammatory respiratory diseases as CF. It will be very
interesting to investigate and correlate the anti-inflamma-
tory effect of bergapten and citropten with their possible
anti-proteinase activity. This double actions could be use-
ful for the treatment of lung inflammation in CF patients.
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